Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jovanovic, R. Stevic, S. Popevic, M. Velinovic, N. Samardzic, D. Maric (Belgrade, Republic Of Serbia). Potential role of antidepressants as part of anticancer therapy. Eur Respir J 2011; 38: Suppl. 55, 2767

Member's Comments

No comment yet.

Related content which might interest you: Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings) Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Next generation of anti-inflammatory therapy for COPD? Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017 Year: 2017 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Therapeutic effects of topical calcilytic in IgE/Th2 and alarmin-driven surrogates of human asthma Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Role of altered immune response in CF and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012